mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug

Mirati Therapeutics, Inc. Common Stock

Sold all MRTX

This member connected a brokerage account and is sharing trades and portfolio performance with the community. 

Public Portfolio

Naveed

Bought 43% more MRTX

Bought 30% more MRTX

New position in MRTX

Miguel Gómez Bravo

Bought 40% more MRTX

Bought 67% more MRTX

Bought to close all MRTX

Mike Pelech

Sold short MRTX

Abilash Satya

Shulem Grunfeld

Bought 100% more MRTX